Lumira Ventures — Full Portfolio

X4 Pharmaceuticals is a biopharmaceutical company developing medicines for people living with rare immune disorders, including chronic neutropenia.

BiotechBoston, US

MDMary DiBiase(Executive Officer)inChristophe Arbet-Engels(Executive Officer)inDavid Kirske(Executive Officer)inJohn Volpone(Executive Officer)inMark Baldry(Executive Officer)ACAdam Craig(Executive Officer, Director)in

Co-investorsBABain Capital Life SciencesNENew Enterprise Associates (NEA)PAPartners ResoluteTHThynk CapitalADAdvent Life SciencesOMOmega Funds+1 more

Zymeworks is a biotechnology company that develops novel therapeutics for patients with difficult-to-treat diseases using its proprietary drug-development platforms and in-house R&D.

BiotechHealthtechVancouver, US

ATALI TEHRANI(Executive Officer, Director)inGORDON NG(Executive Officer)NKNEIL KLOMPAS(Executive Officer)inSDSURJIT DIXIT(Executive Officer)inDAVID TUCKER(Executive Officer)Paul Moore(Chief Scientific Officer)in

Co-investorsBRBrace PharmaCTCTI Life Sciences Fund L.P.HBHBM Healthcare InvestmentsNENextech InvestWUWUTIF CapitalAMAmplitude Venture Capital

Cadence develops a neuromodulation system intended to be a more effective, less invasive treatment for people living with drug-refractory epilepsy.

BiotechDigital HealthHealthtechMedical DevicesSammamish, US

KLKent Leyde(Executive Officer, Director, Promoter)inWarren Douglas Sheffield(Executive Officer, Director, Promoter)

Board seatGBGerry Brunk· per SEC Form D

Co-investorsJAJAZZ Venture PartnersANAngelini VenturesF-F-Prime CapitalIAIaso VenturesMAMayo Clinic Ventures

Cyrano Therapeutics is a clinical-stage regenerative medicine company developing CYR-064, a nasal therapy for post-viral smell loss (hyposmia) and associated loss of taste.

BiotechDigital HealthHealthtechMedical DevicesDelray Beach, US

RGRick Geoffrion(Founder, President and CEO & Board Member)inRichard Geoffrion(Executive Officer, Director)Robert Henkin(Director)

BoardTakahide Koda(Director)

Board seatGBGerry Brunk· per SEC Form D

Co-investorsRERemiges Ventures, Inc.DEDeepWork CapitalFLFlorida Opportunity Fund

SpectraWAVE develops optical and computational imaging technologies to diagnose and guide treatment decisions for patients with coronary artery disease and cardiovascular disease.

AI & Machine LearningDeep TechHealthtechMedical DevicesBedford, US

ENEman Namati(President & CEO)inGTGuillermo Tearney(Founder; Professor of Pathology, Massachusetts General Hospital)GSGregg Stone(Founder; Professor of Medicine, Mount Sinai Heart Health System)JMJames Muller(Founder; Cardiologist, Brigham and Women's Hospital)inJeffrey O'Donnell(Founder; Managing General Partner, Runway Healthcare)VWVivek Walimbe(Chief Operating Officer)in

Board seatGBGerry Brunk· per SEC Form D

Co-investorsS3S3 VenturesSVSV Health InvestorsDEDeerfield Management CompanyJOJohnson & Johnson Innovation – JJDC

Biotheryx is a clinical-stage biopharmaceutical company developing first-in-class targeted protein degraders, including molecular glues and bifunctional degraders, with an initial focus on cancer and inflammatory disease.

BiotechDeep TechMedical DevicesSan Diego, US

Kyle Chan, PhD(Executive Officer)Lawrence Zaslow(Executive Officer, Director)inFrank Mercurio, PhD(Executive Officer)Leah Fung(Chief Executive Officer & Board Member (former Chief Scientific Officer))inRWRaymond W. Urbanski(Acting Chief Medical Officer)inPhilippe Drouet(Chief Executive Officer)in

Co-investorsRERevelation PartnersSRSR One Capital Management

COUR develops antigen-specific immunotherapies that reprogram the immune system to treat the underlying causes of autoimmune and immune-mediated diseases while preserving normal immune function.

BiotechHealthtech

Co-investorsALAlpha Wave GlobalRORoche Venture FundANAngelini VenturesJDJDRF T1D Fund

Thryv Therapeutics is a clinical-stage biotechnology company developing selective inhibitors of serum glucocorticoid inducible kinase 1 (SGK1) for inherited cardiac arrhythmias such as Long QT Syndrome and acquired cardiometabolic diseases.

BiotechHealthtechMedical Devices

PFPaul F. Truex(Chairman of the Board & Chief Executive Officer)inDebra OdinkinASAmy Sehnertin

Co-investorsAMAmzak HealthADadMare BioInnovationsALAlexandriaCTCTI Life Sciences Fund L.P.

Puzzle Medical develops a heart failure treatment device designed to improve heart and kidney function through 4Fr axillary access, allowing patient ambulation and providing up to seven days of support.

HardwareHealthtechMedical DevicesMontreal

Jade Doucet-Martineau(Co-founder & CEO, Board Director)inFrançois Trudeau(Co-founder & CTO, Board Director)inPhilippe Généreux(Co-founder (Phase 2), Chief Medical Officer & Board Observer)inMRMaxime Rochon(Co-founder (Phase 2) & VP Clinical, Regulatory and Quality)inYCYves-Antoine Crête(Co-founder (Phase 2) & VP Technical R&D and Operations)inGGGabriel Georges(Co-founder & Clinical Advisor)in

Co-investorsBRBroadview VenturesAJAjax HealthDEDesjardins CapitalBOBoreal VenturesCACathexis VenturesFRFront Row Ventures+3 more

Thryv Therapeutics is a clinical-stage biotech developing precision-medicine treatments for genetic arrhythmia syndromes and acquired cardiometabolic diseases using selective inhibitors of serum glucocorticoid inducible kinase 1 (SGK1).

BiotechDigital HealthMedical Devices

PFPaul F. Truex(Chairman of the Board & Chief Executive Officer)inDODebra Odink(President & Chief Development Officer)inASAmy Sehnert(Chief Medical Officer)inMKMatt Killeen(Chief Business Officer)in

BoardSDSaumya Das(Chief Scientific Advisor)

Co-investorsADadMare BioInnovationsAMAmzak HealthCTCTI Life Sciences Fund L.P.FOFonds de solidarité FTQ

XyloCor Therapeutics develops gene therapies for advanced coronary artery disease and cardiac damage.

BiotechHealthtechMedical DevicesMalvern, US

RCRonald Crystal(Founder and Advisor (Board Observer))TRTodd Rosengart(Founder; Board Observer)JTJohn Tucker(President and CEO)Albert Gianchetti(Executive Officer, Director)

BoardGBGlenn Batchelder(Director)inJames Cohen(Director)

Co-investorsFOFountain Healthcare PartnersJEJeito CapitalLOLongwood FundSOSofinnova Ventures

Developer of a transcatheter InterAtrial Shunt Device to treat congestive heart failure.

BiotechTewksbury, US

George J. Fazio(Executive Officer, Director)inDan B. Curtis(Executive Officer)

BoardPLPaul LaViolette(Director)inKGKevin Gillis(Director)inGBGerald Brunk(Director)inIYIrit Yaniv(Director)in

Board seatGBGerry Brunk· per SEC Form D

Co-investorsACAccelmed PartnersGEGeneral CatalystSVSV Health InvestorsTHThird Rock Ventures

Endotronix develops the Cordella PA Sensor and Heart Failure System, an FDA-approved implantable pulmonary artery pressure sensor and remote monitoring platform for managing patients with NYHA class III heart failure.

Digital HealthHealthtechMedical DevicesWoodridge, US

HRHarry Rowland(Executive Officer, Director)inANAnthony Nunez(Founder)in

BoardJonathan Jonas(Director)Raymond S. Barrett, Jr.(Director)Sam R. Leno(Director)Leslie A. Saxon(Director)

Board seatGBGerry Brunk· per SEC Form D

Co-investorsAPAPERTURE Venture PartnersBIBioventures InvestorsJUJumpstart VenturesOSOSF VenturesSESeroba Life SciencesSVSV Health Investors+1 more

Company whose formation and launch the LifeSci team supported.

BiotechHealthtechSummit, US

Gregory Mayes(Executive Officer, Director, Promoter)Jouko Isojarvi(Executive Officer)Stephen D. Collins(Director)WLWarren Lammert(Director)inOrrin Devinsky(Director)

Board seatGBGerry Brunk· per SEC Form D

Co-investorsLILifeSci Venture PartnersRERed Tree Venture

Exact Imaging develops the ExactVu micro-ultrasound platform, a 29 MHz imaging system that lets urologists perform real-time targeted and systematic prostate biopsies within a standard workflow.

HardwareHealthtechMedical DevicesMarkham, CA

HWHarold Wodlinger(Director)inRARandy AuCoin(President & CEO)inRSRob Sandler(Executive Officer)inJerrold Wen(Executive Officer)in

BoardWilliam Wortman(Director)GMGaston Matthyssens(Director)

Board seatPVPeter van der Velden· per SEC Form D

Co-investorsIGiGan PartnersPMPMVVEVenture OntarioVEVesalius Biocapital Partners

HistoSonics develops histotripsy technology, a non-invasive method that uses focused sound energy to destroy targeted tissue, offered as a medical device for physicians and their patients.

BiotechHardwareHealthtechMedical DevicesAnn Arbor, GB

TDThomas Davison(Executive Officer, Director)inMCM. Christine Gibbons(Executive Officer, Director)inWen Chen(Director)Tom Tefft(Director)Michael Blue(Executive Officer, Director)Fred Lee(Director)

Board seatGBGerry Brunk· per SEC Form D

Co-investorsALAlpha JWC VenturesALAlpha Wave GlobalAMAmzak HealthARArboretum VenturesCLClarevia VenturesEAEarly Stage Partners, LP+8 more

Medexus Pharmaceuticals is a specialty pharmaceutical company focused on orphan drugs and rare disease treatments, with a portfolio of specialty and rare disease products.

BiotechHealthtechToronto, CA

Ken d'Entremont(Executive Officer, Director)inRoland Boivin(Executive Officer)inTerri Shoemaker(Executive Officer)in

BoardStephen Nelson(Director)Adele Gulfo(Director)

Board seatPVPeter van der Velden· per SEC Form D

BiotechBoston, US

Dr. Richard Peters(Director)Belinda Termeer(Director)DADr. Alan E. Walts(Director)inDr. Gerhard Wagner(Director)SASun Altbach(Executive Officer, Director)in

Board seatGBGerry Brunk· per SEC Form D · $35M raise · filed Oct 2022

Co-investorsADAdvent Life SciencesOROrbiMed

Alpha-9 Oncology develops radiopharmaceuticals for cancer treatment, with a portfolio of molecules in clinical and preclinical development.

BiotechDigital HealthMedical DevicesVancouver, CA

FBFrançois Bénard(Founder)KLKuo-Shyan Lin(Founder)DPDavid Perrin(Founder)

Co-investorsANAndreessen HorowitzASAscenta CapitalDEDelos CapitalFRFrazier Life SciencesGEGeneral CatalystLILightspeed Venture Partners+9 more

Alveolus Bio develops inhaled biotherapeutics for chronic and infectious lung diseases, using a platform that delivers targeted bacteria to the lungs to treat conditions such as idiopathic pulmonary fibrosis, NCFBE, and COPD.

BiotechHealthtech

CVC Vivek Lal(Founder & CSO)inAGAmit Gaggar(Chief Medical Officer)inGMGaurav Mehta(CEO)in

AmacaThera is a biotech company developing a tunable injectable hydrogel drug-delivery platform, based on hyaluronic acid and methylcellulose, for localized and long-acting release of therapeutics such as small molecules, biologics, peptides, and cells.

BiotechDigital HealthMedical DevicesToronto, CA

MCMike Cooke(Co-Founder & CEO)inMSMolly Shoichet(Co-Founder & Chief Science Officer)

Co-investorsINInveready Technology Investment GroupNONorthspring Capital PartnersSTStand Up VenturesTOToronto Innovation Acceleration PartnersMBMBX Capital

Antios Therapeutics develops antiviral therapies for hepatitis B virus (HBV) and other viral diseases, including its Active Site Polymerase Inhibitor Nucleotide (ASPIN) ATI-2173 and a capsid assembly modulator program.

BiotechHealthtechMendham, US

Gregory Mayes(Executive Officer, Director)DMDouglas Mayers(Executive Officer)inTATamra Adams(Executive Officer)inAbel De La Rosa(Director)

BoardIRIyona Rajkomar(Director)inBenjamin Rovinski(Director)

Co-investorsAIAisling CapitalALAltium CapitalAVAvego BioScience CapitalLILifeSci Venture PartnersPOPontifax Venture CapitalAMAmzak Health+8 more

Antiva Biosciences develops a topical therapeutic for women with high-risk HPV infection and pre-cancerous cervical lesions, utilizing antiviral prodrug chemistry.

BiotechFemTechHealthtechMedical DevicesRedwood City, US

KYKarl Y. Hostetler(Executive Officer, Director)inGMGail Maderis(Director)inKBKristine Ball(President & CEO)inECElaine Chien(Executive Officer)inSarah Walter(Executive Officer)inRGRaju Gadiraju(Executive Officer)in

Co-investorsADAdjuvant CapitalAVAvestria VenturesBRBrace PharmaCACanaan PartnersGAGaingelsGVGV (Google Ventures)+6 more

Aurinia is a biopharmaceutical company developing therapies for autoimmune diseases with significant unmet medical needs.

BiotechDigital HealthHealthtechMedical DevicesVictoria, US

RMRichard M. Glickman(Executive Officer, Director)inStephen W. Zaruby(Executive Officer, Director)MMMichael Martin(Executive Officer, Director)inDennis Bourgeault(Executive Officer)Mr. Tang(Chief Executive Officer and Chair of the Board)

BoardKVKurt von Emster(Director)in

Co-investorsNENew Enterprise Associates (NEA)VEvenBio Partners

Axonis Therapeutics is a biotechnology company developing small-molecule medicines that target KCC2, a mediator of inhibition in the brain, to treat neurological disorders such as epilepsy and pain.

BiotechDeep TechBoston, US

SVShane V. Hegarty(Chief Scientific Officer & Co-Founder)inJSJoanna Stanicka(Chief Executive Officer, President & Co-Founder)inJIJeff Imbaro(Chief Operating Officer)inTSTiasha Shafiq(Chief of Staff)in

BoardC.Corey . Goodman(Director)inJLJonathan Leff(Director)in

Co-investorsSOSofinnova VenturesVEvenBio PartnersMRMRL Ventures FundCICivilization Ventures Management, LlcCRCreative Destruction Lab (CDL)HAHatteras Venture Partners+8 more

BardyDx develops the Carnation Ambulatory Monitor (CAM), a lightweight cardiac patch monitor designed for extended-wear ambulatory ECG monitoring that emphasizes P-wave signal clarity.

Digital HealthHealthtechMedical DevicesSeattle, US

Gust H. Bardy(Executive Officer, Director, Promoter)Mark Querry(Executive Officer)Kevin Nelson, III(Executive Officer)Rik Vandevenne(Director)Alan Levy(Director)Mark Handfelt(Executive Officer, Promoter)

Co-investorsAPAPERTURE Venture PartnersAPAphelion CapitalASAscension VenturesRCRC CapitalRERex Health VenturesSVSV Health Investors+2 more

Bright Angel Therapeutics is a pre-clinical stage biotechnology company developing small-molecule antifungal therapeutics aimed at drug-resistant and life-threatening invasive fungal infections.

BiotechDeep TechToronto, CA

Leah Cowen(Co-founder & CSO)LWLuke Whitesell(Co-founder & Consultant)Dominic Jaikaran(President & CEO)in

Co-investorsTOToronto Innovation Acceleration Partners

Cardiac Dimensions develops medical technology to treat heart failure caused by functional mitral regurgitation (FMR), aiming to address underlying causes rather than symptoms.

BiotechHealthtechMedical DevicesKirkland, US

Frederick A. Stewart(Executive Officer, Director)RWRick Wypych(Executive Officer)in

BoardKurt Wheeler(Director)Nathan Every(Director)Douglas C. Fisher(Director)GBGerry Brunk(Director)in

Co-investorsAPAPERTURE Venture PartnersRERedbus VenturesALAlly Bridge GroupCLClaret Capital PartnersJEJefferiesM.M.H. Carnegie & Co.

Congruence is a drug discovery company that applies protein dynamics, biophysics, machine learning, and computational chemistry to model proteins in their full dynamic state and predict disease correction in silico.

AI & Machine LearningBiotechDeep Tech

CDClarissa Desjardins(Founder)in

Co-investorsOROrbiMedALAlexandriaDIDIMENSIONANAngelini VenturesBDBDC Thrive Venture Fund for WomenAMAmplitude Venture Capital+1 more

Contraline develops new contraceptive and reproductive health technologies, with a focus on male contraception.

BiotechDigital HealthMedical DevicesCharlottesville, US

KEKevin Eisenfrats(Founder)inJohn Herr(Founder)

BoardIris Van Alderwerelt van Rosenburgh(Director)GBGurdane Bhutani(Director)inMartin J Emerson(Director)Tom Thorpe(Director)

Co-investorsBIBiotechnology Value FundMBMBX CapitalALAllied Venture PartnersALAlumni VenturesAMAmboy Street VenturesAUAurum Venture Partners+19 more

Gilead discovers, develops, and delivers innovative therapeutics for people with life-threatening diseases, focusing on virology, oncology, and inflammation across more than 35 countries.

BiotechDigital HealthHealthtechMedical DevicesFoster City, US

LLLou Lange(Founder)MLMichael L. Riordan(Founder)inDODaniel O'Dayin

Co-investorsAIAisling CapitalASAsset Management CompanyFRFrazier Life SciencesKLKleiner PerkinsLOLongitude CapitalMEMenlo Ventures+6 more

Damona develops precision neuromedicines aimed at treating cognitive deficits associated with neurodegenerative and psychiatric disorders such as Alzheimer's disease, depression, and schizophrenia.

BiotechDeep TechDigital HealthHealthtechMedical Devices

Co-investorsANAngelini VenturesNONoeticTOToronto Innovation Acceleration Partners

BiotechGermantown, US

JMJohn Mumm(Executive Officer, Director)Vera Mumm(Executive Officer)Pavel Khrimian(Executive Officer, Director)Lucio Iannone(Director)Sally (Yuanheng) Wang(Director)

BoardLHLu Han(Director)in

Co-investorsATATEM Capital FundPLPlains VenturesECEcho Investment CapitalLELeaps by BayerMPMPM BioImpact

Endogenex is a clinical-stage medical device company developing the pulsENDO system, which applies non-thermal pulsed electric field to reset the body's metabolic signaling and improve function in people with type 2 diabetes.

Digital HealthHealthtechMedical DevicesMinneapolis, US

SPStacey Pugh(Leadership (CEO))inChris Sorli, MD, PhD(Chief Medical Officer)inKrissy Wright(Chief Financial Officer)inLian Cunningham, MD, PhD(VP Clinical Affairs)inMHMelanie Hess(Regulatory Affairs Leadership)inMCMatt Cambronne(Technical/Engineering Leadership)in

Co-investorsARArboretum VenturesHAHatteras Venture PartnersINIntuitive VenturesLOLongitude CapitalSOSoutheast Minnesota Capital Fund

enGene is a genetic medicine company developing drug therapies across oncology, urology, and other therapeutic areas, with a focus on patient outcomes.

BiotechMedical Devices

Co-investorsCTCTI Life Sciences Fund L.P.

Fusion Pharma develops targeted alpha therapeutics that link alpha-emitting medical isotopes to molecules targeting biomarkers on cancer cell surfaces to selectively kill tumor cells.

BiotechHealthtech

JVJohn Valliant(Founder)in

Co-investorsFAFACIT (Fight Against Cancer Innovation Trust)GEGenesys CapitalHEHealthCapPIPivotal Life SciencesSESeroba Life SciencesVEVenture Ontario+6 more

G1 Therapeutics develops cancer therapies focused on improving patient outcomes and quality of life for people with cancer.

BiotechResearch Triangle Park, US

Jay Strum(Executive Officer)NSNorman Sharpless(Director)MAMark A. Velleca(Executive Officer, Director)inThomas K Laundon(Executive Officer)Timothy Sullivan(Director)Gregory Mossinghoff(Executive Officer)

Co-investorsHAHatteras Venture PartnersMOMountain Group CapitalRARA CapitalSOSolasta Ventures

Cytek Biosciences develops full spectrum (spectral) flow cytometry instruments, reagents, and software tools for researchers, enabling large multicolor panels of 40 colors and beyond from a single sample tube.

BiotechHardwareHealthtechBellevue, US

Iterion Therapeutics is a clinical-stage biopharmaceutical company developing cancer therapies targeting the Wnt/β-catenin pathway.

BiotechHealthtech

RARahul Aras(Chief Executive Officer)inOTOvid Trifan(Chief Medical Officer)inSHSteve Horrigan(Chief Scientific Officer)in

Co-investorsGRGreen Park & Golf VenturesPOPortal Innovations

KisoJi Biotechnology discovers and develops differentiated antibody therapeutics targeting difficult targets in oncology and other diseases.

AI & Machine LearningBiotechDeep Tech

Co-investorsRERemiges Ventures, Inc.

Developed a robotic surgical arm for knee and hip arthroplasty; acquired by Stryker for $1.65B in 2013.

Co-investorsAPAPERTURE Venture PartnersMOMontreux Equity Partners

Nervonik develops peripheral nerve stimulation (PNS) systems designed for high-motion, dynamic activity, using a patented technology that adds biosensing and objective feedback to neuromodulation.

HardwareHealthtechMedical Devices

Co-investorsFOFoothill VenturesJOJoyance PartnersSHShangBay Capital LLCUSUS Venture PartnersAMAmzak HealthU.U.S. Venture Partners

Nocion Therapeutics develops small molecule charged sodium channel blockers (nocions) designed to silence overactive sensory nerves.

BiotechHealthtechMedical DevicesWatertown, US

MATTHEW FRANKEL(Executive Officer)inPCPETER COUROSSI(Executive Officer)RICHARD BATYCKY(President and Chief Executive Officer)JAMES ELLIS(Executive Officer)MLMICHAEL LIPP(Executive Officer)inCSCHRISTOPHER SILBER(Executive Officer)in

Co-investorsCACanaan PartnersF-F-Prime CapitalMIMission BiocapitalMOMonograph Capital PartnersOUOUP (Osage University Partners)

BiotechPhoenix, US

Douglas Grant McFadden, Ph.D.(Director)Steven J. Potts, Ph.D.(President and Chief Executive Officer)Ting Xiao(Director)JRJason Rushton(Director)Kanad Das, Ph.D.(Director)Michael G. Wood(Executive Officer)

Co-investorsXEXeraya CapitalB B Capital GroupBOBoehringer Ingelheim Venture FundCICity Hill VenturesDEDelos CapitalKOKorea Investment Partners+1 more

OpSens Medical develops sensor-guided medical devices, including fiber optic guidewires and hemodynamic monitoring systems, for use in interventional cardiology procedures.

Digital HealthMedical Devices

Satsuma Pharmaceuticals develops therapeutics for the acute treatment of migraine, including an approved dihydroergotamine nasal powder product (Atzumi/STS101).

BiotechHealthtechMedical DevicesSouth San Francisco, US

JKJohn Kollins(Executive Officer, Director)Tadayoshi Iwashima(Executive Officer)TBThomas B. King(President and Board Director)inRJRob Janosky(Chief Commercial Officer)TOTom O'Neil(Chief Financial Officer)inDavid Prichard(Chief Operating Officer)

Co-investorsOUOUP (Osage University Partners)VIVivo CapitalWEWellington ManagementRARA CapitalRERed Tree VentureSBSBI Investment

SoundBlade Medical develops handheld histotripsy technology for non-invasive surgery, using focused ultrasound to treat tissue with precision.

HardwareHealthtechMedical Devices

JBJeremy Brown(Co-Founder & CTO)inMMMatt Mallay(Co-Founder & Sr. Dir. R&D)inABAndre Bezanson(Co-Founder & Dir. R&D)inEVEli Vlaisavljevich(Co-Founder)inRBRick Balys(Co-Founder)inNBNeil Barman(Chief Executive Officer)in

Co-investorsAMAmzak HealthAPAPERTURE Venture PartnersINInvest Nova Scotia

Specific Biologics develops in vivo genome editing therapeutics based on its Dualase editors, which use a two-site mechanism to remove, repair, or insert DNA sequences, with an initial focus on correcting expanded DNA repeats.

BiotechDeep TechHealthtech

HealthtechSunnyvale, US

Thomas Afzal(Executive Officer, Director)

BoardPVPeter van der Velden(Director)inDavid Milne(Director)Dan Galles(Director)Mark Brooks(Director)Richard Ferrari(Director)

Co-investorsHLHLM Investment PartnersSVSV Health InvestorsSVSV Life Sciences

Think Research works with health systems to improve care delivery through clinical software, clinical expertise, and hands-on operational support across access to care, clinical workflow, and medication safety.

Digital HealthHealthtechSaaS

Co-investorsIGiGan Partners

Transposon Therapeutics is a biotechnology company developing therapies for neurodegenerative and aging-related diseases, with a pipeline that includes its lead candidate TPN-101 and novel NRTIs targeting conditions such as PSP, ALS/FTD, and Alzheimer's disease.

BiotechHealthtechLongevitySan Diego, US

DPDennis Podlesak(Executive Officer, Director)LRLynne R. Rollins(Executive Officer)EWEckard Weber, MD(Executive Officer, Director)EWEckard Weber, M.D.(Executive Officer, Director)in

BoardDaniel Hetu, MD, MBA(Director)BABrent Ahrens(Director)in

Co-investorsCACanaan Partners